NASDAQ: TMDXTransmedics Group Inc Stock
$87.86-5.45 (-5.84%)
Updated Apr 17, 2024
TMDX Price
$87.86
Fair Value Price
N/A
Market Cap
$2.87B
52 Week Low
$36.42
52 Week High
$99.63
P/E
-114.1x
P/B
20.95x
P/S
10.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$241.62M
Earnings
-$25.03M
Gross Margin
63.8%
Operating Margin
-6.57%
Profit Margin
-10.4%
Debt to Equity
4.15
Operating Cash Flow
-$13M
Beta
1.31
Next Earnings
Apr 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TMDX Overview
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TMDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TMDX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TMDX is poor value based on its book value relative to its share price (20.95x), compared to the US Medical Devices industry average (3.66x)
P/B vs Industry Valuation
TMDX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TMDX due diligence checks available for Premium users.
Be the first to know about important TMDX news, forecast changes, insider trades & much more!
TMDX News
Valuation
TMDX fair value
Fair Value of TMDX stock based on Discounted Cash Flow (DCF)
Price
$87.86
Fair Value
-$0.09
Undervalued by
102,998.16%
TMDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TMDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-114.1x
Industry
28.84x
Market
41.64x
TMDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
20.95x
Industry
3.66x
TMDX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TMDX's financial health
Profit margin
Revenue
$81.2M
Net Income
$4.0M
Profit Margin
5%
TMDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TMDX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$706.0M
Liabilities
$568.8M
Debt to equity
4.15
TMDX's short-term assets ($510.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TMDX's long-term liabilities ($513.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TMDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TMDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$8.3M
Investing
-$41.8M
Financing
$924.0k
TMDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TMDX vs Medical Device Stocks
Transmedics Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.